Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Gilead Sciences clinical trials
The registry lists 734 studies whose lead sponsor is Gilead Sciences or one of 2 companies grouped under it. 33 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Gilead Sciences studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Gilead Sciences.
- Gilead Sciences689 studiesSame company
Something wrong?
- Kite, A Gilead Company39 studies →Acquired — became part of Gilead Sciences, Oct 3, 2017 · source ↗
Something wrong?
- 6 studies →
Focus areas
Conditions Gilead Sciences leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 734. Browse all 734 →
- Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsRecruitingNCT07128303Phase 1
- Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsRecruitingNCT07841990Phase 2
- Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruitingNCT06626919Phase 1
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07887672Phase 3
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionRecruitingNCT07473778
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingNCT06801834Phase 3
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingNCT07527858Phase 2
- Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentRecruitingNCT07304154Phase 1
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingNCT06337032Phase 4
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingNCT07645287Phase 2
- Study of GS-2426 in Participants With Advanced Solid TumorsRecruitingNCT07601243Phase 1
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingNCT05633654Phase 3
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingNCT07708727Phase 2/3
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyRecruitingNCT07479797Phase 3
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Phase 3
- Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)RecruitingNCT06562907Phase 1
- A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesEnrolling by invitationNCT07038447Phase 1
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisNot yet recruitingNCT07841977Phase 2
- Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaRecruitingNCT04989803Phase 1/2
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- Study of GS-0415 and How It Works in People With HIVRecruitingNCT07719491Phase 1
- Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesEnrolling by invitationNCT05041309
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasRecruitingNCT07546812Phase 2
- A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid TumorsRecruitingNCT07703878Phase 1
- Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusRecruitingNCT07096193Phase 1/2
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyRecruitingNCT07682961Phase 3
- Study of GS-0201 Alone and in Combination in Participants With Advanced Solid TumorsRecruitingNCT06167317Phase 1
- Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensRecruitingNCT07683000Phase 3
- Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelAvailableNCT05776160
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentRecruitingNCT04617522Phase 1
- Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and ChildrenRecruitingNCT06749054Phase 2
- Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid TumorsRecruitingNCT06532565Phase 1
- Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAvailableNCT05776134
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerRecruitingNCT06926920Phase 1/2
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)Active, not recruitingNCT06486441Phase 3
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Active, not recruitingNCT05502341Phase 2/3
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionActive, not recruitingNCT04994509Phase 3
- Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionActive, not recruitingNCT04925752Phase 3
- Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.Active, not recruitingNCT05457010Phase 1
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences
- Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug ResistanceActive, not recruitingNCT04150068Phase 2/3
- Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1Active, not recruitingNCT06532656Phase 2/3
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1Active, not recruitingNCT02881320Phase 2/3
- Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With GoutCompletedNCT01336686Phase 2
- Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutCompletedNCT02252835Phase 2
- Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on MetforminTerminatedNCT00814372Phase 2
- Study of Bulevirtide in Participants With Chronic Hepatitis D InfectionTerminatedNCT05718700
- Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 DiabetesCompletedNCT01035879Phase 2
- Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsActive, not recruitingNCT05007782Phase 1
- Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT05186974Phase 2
- Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06029972Phase 2
- A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous TreatmentActive, not recruitingNCT06539338Phase 1
Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences